Wabash: Cash Is King, Especially In The Current Environment

MetLife: Investors Should Look Past The Noisy Q2 2022 Results

American Equity's Growth Strategy: Playing Out According To Plan

Charles River Laboratories' Long-Term Story Is Still Intact

Summary:

- Charles River recently reported impressive Q1 2018 financial results that beat the top- and bottom-line estimates.

- The Discovery and Safety Assessment, or DSA, unit greatly contributed to the company's strong Q1 2018 financial results.

- I plan to stay long Charles River.

Charles River Laboratories ($CRL) is scheduled to release Q2 2018 financial results on August 8, 2018, and analysts expect for the company to report adjusted EPS of $1.47 on revenue of $569.4M. For comparison purpose, the company reported adjusted EPS of $1.29 on revenue of $469.1M in the same quarter of the prior year.

The stock of this drug discovery and early-stage development company has performed well so far in 2018, as CRL shares have outperformed the S&P 500 by over 200 bps on a YTD basis.

The outperformance should continue through at least the remainder of 2018, in my opinion, because, as I previously described here, I believe that Charles River is well-positioned for 2018 and beyond.